British Journal of Cancer · 2005 · 26 citations · 38 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMedical OncologyChemotherapy Toxicity ManagementCombination ChemotherapyDose Adjustment In OncologyLung Cancer PharmacotherapyOncology PharmacologyToxicity ManagementChemotherapy Dose OptimizationChemotherapy Dosing AdjustmentsIrinotecan-based TherapyMedian AgeNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPartial Response Assessment
Our purpose was to determine the efficacy of irinotecan plus paclitaxel administered on day 1, repeated every 2 weeks, in untreated patients with advanced or metastatic non-small-cell lung cancer (NSCLC). In total, 56 patients with inoperable or metastatic stage III and IV NSCLC with a histologically or cytologically confirmed diagnosis were enrolled. None of the patients had undergone prior chemotherapy or radiation therapy. Treatment involved irinotecan 125 mg m(-2) and paclitaxel 135 mg m(-2) administered on day 1 and repeated every 2 weeks for a planned number of nine cycles. With a standard dose of paclitaxel at 135 mg m(-2), the dosage of irinotecan was escalated at four levels: 75, 100, 125 and 150 mg m(-2); 125 mg m(-2) was established as the maximum tolerated dose; this dosage was administered to 46 patients. A total of 52 patients (median age 65 years, range 38-77 years) were assessable for toxicity and survival and 46 for response rate. Out of 46 evaluable patients, 19 achieved partial response (41.3%), 17 had stable disease (37%) and 10 (21.7%) experienced disease progression. The median duration of response was 6 months (range 2-9+ months). The main adverse reactions were myelotoxicity (grades 3 and 4) in 10 (19.2%) patients and diarrhoea (grade 3) in four (7.7%) patients. Irinotecan combined with paclitaxel, administered every 2 weeks, appears to be an effective treatment for advanced-stage NSCLC.
38
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Leonard B. Saltz, John V. Cox, Charles D. Blanke et al. · New England Journal of Medicine · 2000 · 3K citations · Full text
Medicine, Oncology, Pharmacology +13
Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton et al. · Journal of Clinical Oncology · 2003 · 2.3K citations
Medicine, Oncology, Pharmacology +15
David H. Johnson, Louis Fehrenbacher, William Novotny et al. · Journal of Clinical Oncology · 2004 · 1.9K citations · Full text
Medicine, Oncology, Pharmacology +11